Modeling effects of SGLT ‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
Year: 2014
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12261
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Bristol-Myers Squibb, AstraZeneca
OpenAlex ID: W1503352903
